Therefore, agonistic anti-DCIR antibodies could provide therapeutic benefits for chronic diseases driven by neutrophil-mediated pathology, including chronic obstructive pulmonary disease (COPD), neutrophilic asthma, RA, and gouty arthritis. The gene discussed is CLEC4A; the disease is rheumatoid arthritis.